JP2016517888A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517888A5
JP2016517888A5 JP2016512081A JP2016512081A JP2016517888A5 JP 2016517888 A5 JP2016517888 A5 JP 2016517888A5 JP 2016512081 A JP2016512081 A JP 2016512081A JP 2016512081 A JP2016512081 A JP 2016512081A JP 2016517888 A5 JP2016517888 A5 JP 2016517888A5
Authority
JP
Japan
Prior art keywords
compound
therapeutic agent
hydrogen
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517888A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/036680 external-priority patent/WO2014179756A1/en
Publication of JP2016517888A publication Critical patent/JP2016517888A/ja
Publication of JP2016517888A5 publication Critical patent/JP2016517888A5/ja
Pending legal-status Critical Current

Links

JP2016512081A 2013-05-02 2014-05-02 骨選択的骨形成のオキシステロール骨標的薬剤 Pending JP2016517888A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361818825P 2013-05-02 2013-05-02
US61/818,825 2013-05-02
PCT/US2014/036680 WO2014179756A1 (en) 2013-05-02 2014-05-02 Bone-selective osteogenic oxysterol-bone targeting agents

Publications (2)

Publication Number Publication Date
JP2016517888A JP2016517888A (ja) 2016-06-20
JP2016517888A5 true JP2016517888A5 (enExample) 2017-06-15

Family

ID=51844004

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512081A Pending JP2016517888A (ja) 2013-05-02 2014-05-02 骨選択的骨形成のオキシステロール骨標的薬剤

Country Status (7)

Country Link
US (1) US9683009B2 (enExample)
EP (1) EP2991652A4 (enExample)
JP (1) JP2016517888A (enExample)
CN (1) CN105263500A (enExample)
AU (1) AU2014259672A1 (enExample)
CA (1) CA2911205A1 (enExample)
WO (1) WO2014179756A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1993558B1 (en) 2006-02-27 2014-07-30 The Regents of The University of California Oxysterol compounds and the hedgehog pathway
CN104395331B (zh) 2012-05-07 2016-11-02 加利福尼亚大学董事会 诱导骨生成和hedgehog 信号传导且抑制脂肪形成的氧固醇类似物氧固醇化合物133
EP2991652A4 (en) 2013-05-02 2016-12-07 Univ California BONE-LAYERED BONE-RELATED OSTEOGENIC OXYSTEROL AGENTS
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
KR20170101940A (ko) * 2014-12-09 2017-09-06 워쏘우 오르쏘페딕 인코포레이티드 스테롤 관련 화합물 및 방법
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US9878070B2 (en) 2015-06-17 2018-01-30 Warsaw Orthopedic, Inc. Malleable implants including an oxysterol and methods of use
US9877836B2 (en) 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
US12171909B2 (en) 2015-07-10 2024-12-24 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
US9637514B1 (en) * 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
AU2016347052B2 (en) * 2015-10-27 2021-03-25 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
CA3048220A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US10294264B2 (en) * 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
KR102318505B1 (ko) * 2019-04-26 2021-10-27 서울대학교산학협력단 골 세포 전환 재조합 단백질 및 골 표적화 분자를 포함하는 골 특이적 복합체

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB869007A (en) 1956-10-03 1961-05-25 Ciba Ltd New heterocyclically substituted steroids
CH433275A (de) 1963-07-09 1967-04-15 Hoffmann La Roche Verfahren zur Herstellung von 19-Alkylsteroiden
JPS5111114B1 (enExample) 1969-03-14 1976-04-08
US3887545A (en) 1973-11-12 1975-06-03 Hoffmann La Roche Synthesis of 1{60 -hydroxylated cholesterol derivatives
US4264512A (en) 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4743597A (en) 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
LU87201A1 (fr) 1988-04-14 1989-11-14 Cird Complexes a base d'anthraline et d'un sterol,leur procede d'obtention et leur utilisation en therapeutique et cosmetique
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
CA2066053C (en) 1989-08-18 2001-12-11 Harry E. Gruber Recombinant retroviruses delivering vector constructs to target cells
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
GB9118465D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
US7060450B1 (en) 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
DE69519368T2 (de) 1994-01-06 2001-03-08 Sri International, Menlo Park Neue antiandrogenen mitteln pharmazeutische präparate und verwendungen davon
ATE363908T1 (de) 1996-04-09 2007-06-15 Univ Edinburgh Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen
ES2329953T3 (es) 1996-04-19 2009-12-02 Osiris Therapeutics, Inc. Regeneracion e incremento de hueso utilizando celulas madre mesenquimales.
US6893830B1 (en) 1996-09-27 2005-05-17 The Board Of Regents Of The University Of Texas System Method of screening oxysterol activation of LXRα
US5840752A (en) 1996-11-21 1998-11-24 Henry; James P. Reduction of hair growth
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6080779A (en) 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
BR9806989A (pt) 1997-01-24 2000-03-14 Univ California Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero.
JP2001526673A (ja) 1997-05-16 2001-12-18 アクゾ・ノベル・エヌ・ベー ２０−アルアルキル−５α−プレグナン誘導体
DE19723794A1 (de) 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US5929062A (en) 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
WO1999000117A2 (en) 1997-06-27 1999-01-07 Ontogeny, Inc. Neuroprotective methods and reagents
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
WO1999045923A1 (en) 1998-03-13 1999-09-16 Merck & Co., Inc. Methods of inhibiting bone resorption
EP0943332A1 (en) 1998-03-19 1999-09-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Prevention and treatment of adhesions
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
US6518262B1 (en) 1999-03-09 2003-02-11 Akzo Nobel N.V. 22R-hydroxycholesta-8, 14-diene derivatives for the inhibition of meiosis
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6586189B2 (en) 1999-06-18 2003-07-01 City Of Hope Screening method for PPAR-γ ligands
AU1291901A (en) 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
WO2001094379A2 (en) 2000-06-08 2001-12-13 The Regents Of The University Of California Methods and compositions for controlled synthesis of amino acid polymers
US20020115695A1 (en) 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
GB0101933D0 (en) 2001-01-25 2001-03-07 Astrazeneca Ab Therapy
KR101050377B1 (ko) 2001-02-12 2011-07-20 에이에스엠 아메리카, 인코포레이티드 반도체 박막 증착을 위한 개선된 공정
WO2002080952A2 (en) 2001-04-09 2002-10-17 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
WO2003077869A2 (en) 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Neuroprotective spirostenol pharmaceutical compositions
CA2495882A1 (en) 2002-08-29 2004-03-11 The Regents Of The University Of California Agents and methods for enhancing bone formation
DE10307104A1 (de) 2003-02-19 2004-09-23 Schering Ag Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate
JP2007525470A (ja) 2003-07-09 2007-09-06 フォーブス メディ−テック インコーポレーテッド ステロール及び／又はスタノール及びコレステロール生合成阻害剤を含む新規化合物及び組成物、並びに様々な疾患及び症状の治療又は防止へのそれらの使用
WO2005028616A2 (en) 2003-07-24 2005-03-31 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and methods of use thereof to treat heart disorders
WO2005019264A2 (en) 2003-08-18 2005-03-03 Wyeth Human lxr alpha variants
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
EP1697300A4 (en) 2003-12-24 2007-10-03 Univ Louisville Res Found BONE TISSUE TARGETING COMPOUNDS FOR ADMINISTRATION TO BONE OF CON US AGENTS FOR INTERACTING WITH BONE
AU2005254949A1 (en) 2004-06-10 2005-12-29 Merck & Co., Inc. Estrogen receptor modulators
WO2006012902A2 (en) 2004-08-02 2006-02-09 Novozymes A/S Creation of diversity in polypeptides
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
WO2006110490A2 (en) 2005-04-07 2006-10-19 The Regents Of The University Of California Agents and methods for osteogenic oxysterols inhibition of oxidative stress on osteogenic cellular differentiation
CN104017083A (zh) 2005-04-15 2014-09-03 亚利桑那癌症治疗公司 用于治疗转移性癌症的治疗肽
JP2009512422A (ja) 2005-09-02 2009-03-26 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 骨形成及び抗脂肪細胞形成オキシステロール類
EP1993558B1 (en) 2006-02-27 2014-07-30 The Regents of The University of California Oxysterol compounds and the hedgehog pathway
WO2008011071A2 (en) 2006-07-19 2008-01-24 The Regents Of The University Of California Interactions of hedgehog and liver x receptor signaling pathways
US20080070883A1 (en) 2006-09-19 2008-03-20 Wyeth Use of LXR modulators for the prevention and treatment of skin aging
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
AU2007339325A1 (en) 2006-12-19 2008-07-10 The Regents Of The University Of California Inhibition of PPAR gamma expression by specific osteogenic oxysterols
US8071575B2 (en) * 2007-02-23 2011-12-06 University Of Louisville Research Foundation Methods and compounds for the targeted delivery of agents to bone for interaction therewith
WO2008109780A1 (en) * 2007-03-06 2008-09-12 University Of Louisville Research Foundation, Inc Methods and compounds for the targeted delivery of agents to bone for interaction therewith
US20100112030A1 (en) 2007-03-16 2010-05-06 The Regents Of The University Of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2009073186A1 (en) 2007-12-03 2009-06-11 The Regents Of The University Of California Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
MY163799A (en) 2008-02-07 2017-10-24 Dsg Tech Holdings Limited Method of making an absorbent composite and absorbent articles employing the same
WO2011006087A1 (en) 2009-07-10 2011-01-13 The Regents Of The University Of California Inhibition of ppar gamma expression in preadipocyte cells by oxysterols
US20120309730A1 (en) 2010-02-16 2012-12-06 The Johns Hopkins University Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
WO2012024584A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024583A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024581A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
CN104395331B (zh) * 2012-05-07 2016-11-02 加利福尼亚大学董事会 诱导骨生成和hedgehog 信号传导且抑制脂肪形成的氧固醇类似物氧固醇化合物133
AU2013260057A1 (en) 2012-05-07 2014-11-27 The Regents Of The University Of California Novel oxysterol analogue, Oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
EP2991652A4 (en) 2013-05-02 2016-12-07 Univ California BONE-LAYERED BONE-RELATED OSTEOGENIC OXYSTEROL AGENTS
CN106232612B (zh) 2014-05-02 2019-01-29 加利福尼亚大学董事会 骨选择性成骨性氧固醇双膦酸盐类似物

Similar Documents

Publication Publication Date Title
JP2016517888A5 (enExample)
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
JP2015500225A5 (enExample)
HK1205156A1 (en) Cyclodextrin-based polymers for therapeutic delivery
JP2015511609A5 (enExample)
JP2012136540A5 (enExample)
JP2011102304A5 (enExample)
WO2015042078A8 (en) Substituted aminopyrimidine compounds and methods of use
IN2012DN06720A (enExample)
JP2014508752A5 (enExample)
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2015524444A5 (enExample)
JP2015532296A5 (enExample)
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MY160652A (en) Pharmaceutical composition for oral administration
PH12015500823A1 (en) Modified release formulations for oprozomib
WO2016040814A3 (en) Disulfide polymers and methods of use
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
JP2013541582A5 (enExample)
JP2015524460A5 (enExample)
MX2013007959A (es) Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
JP2017530142A5 (enExample)